Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH

MT Newswires Live08-03

Altimmune (ALT) said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.

Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.

The company said it expects to publish a 52-week data readout from the trial in 2029.

Shares of the company were up 1.4% in Monday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656744853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656744853","market":"hk","top_or_hot":-1,"title":"Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH","media":"MT Newswires Live","content":"<html><body><p> Altimmune (ALT) said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.</p><p>Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.</p><p>The company said it expects to publish a 52-week data readout from the trial in 2029.</p><p>Shares of the company were up 1.4% in Monday's premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-03 21:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Altimmune (ALT) said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.</p><p>Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.</p><p>The company said it expects to publish a 52-week data readout from the trial in 2029.</p><p>Shares of the company were up 1.4% in Monday's premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"减肥药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656744853","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656744853","pubTimestamp":1785763789,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Altimmune  said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.The company said it expects to publish a 52-week data readout from the trial in 2029.Shares of the company were up 1.4% in Monday's premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4599":"减肥药","ALT":"Altimmune, Inc.","BK4139":"生物科技","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC"},"translate_title":"Altimmune 开始招募 Pemvidutide MASH 3 期试验患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":1},"content_text":"Altimmune (ALT) said Monday it has started enrolling patients in the phase 3 PERFORMA trial evaluating pemvidutide in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The global, randomized, double-blind, placebo-controlled study aims to evaluate the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate-to-advanced fibrosis, the company said.Altimmune said that the trial follows findings from the phase 2b IMPACT trial and incorporates feedback from the US Food and Drug Administration and European regulatory agencies.The company said it expects to publish a 52-week data readout from the trial in 2029.Shares of the company were up 1.4% in Monday's premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656744853","isCrawlerRequest":true}